Skip to main content
Journal cover image

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.

Publication ,  Journal Article
Kolb, EA; Gorlick, R; Keir, ST; Maris, JM; Lock, R; Carol, H; Kurmasheva, RT; Reynolds, CP; Kang, MH; Wu, J; Houghton, PJ; Smith, MA
Published in: Pediatr Blood Cancer
May 2012

RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling. The activity of RO4929097 was evaluated against the in vivo panels of the Pediatric Preclinical Testing Program (PPTP). RO4929097 induced significant differences in event-free survival (EFS) distribution compared to control in 6 of 26 (23%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts. The most consistent tumor growth delay effects were noted in the osteosarcoma panel. RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

May 2012

Volume

58

Issue

5

Start / End Page

815 / 818

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Signal Transduction
  • Receptors, Notch
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Mice, Inbred BALB C
  • Mice
  • Humans
  • Female
  • Drug Evaluation, Preclinical
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Lock, R., Carol, H., … Smith, M. A. (2012). Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer, 58(5), 815–818. https://doi.org/10.1002/pbc.23290
Kolb, E Anders, Richard Gorlick, Stephen T. Keir, John M. Maris, Richard Lock, Hernan Carol, Raushan T. Kurmasheva, et al. “Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Pediatr Blood Cancer 58, no. 5 (May 2012): 815–18. https://doi.org/10.1002/pbc.23290.
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 2012 May;58(5):815–8.
Kolb, E. Anders, et al. “Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Pediatr Blood Cancer, vol. 58, no. 5, May 2012, pp. 815–18. Pubmed, doi:10.1002/pbc.23290.
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 2012 May;58(5):815–818.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

May 2012

Volume

58

Issue

5

Start / End Page

815 / 818

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Signal Transduction
  • Receptors, Notch
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Mice, Inbred BALB C
  • Mice
  • Humans
  • Female
  • Drug Evaluation, Preclinical